What is the difference between Bifidobacterium breve M-15 and M-16V?

M-15 and M-16V are distinct sub-strains of Bifidobacterium breve, differentiated by their specific genomic sequences, surface protein profiles, and potentially their colonization kinetics. All published clinical research to date has used the M-16V strain, particularly in preterm infant studies, meaning efficacy and safety data cannot be directly transferred to M-15 without independent trials.

Is Bifidobacterium breve M-15 safe for newborns or premature infants?

No clinical safety data exists specifically for B. breve M-15 in neonates or preterm infants; safety inferences would have to be extrapolated from M-16V studies, which demonstrated tolerability in preterm infants at doses supporting colonization up to 8.6 log cells per gram of stool. Parents and clinicians should consult a neonatologist before administering any unstudied probiotic strain to premature or medically fragile infants.

What dose of Bifidobacterium breve M-15 should I take?

No dosing regimen has been established for B. breve M-15 through clinical trials, making it impossible to give an evidence-based recommendation for this specific strain. Related M-16V research in preterm infants typically employed doses in the range of 1–3 billion CFU (colony-forming units) per day, but these findings cannot be reliably applied to M-15 or to adult populations without dedicated studies.

Can Bifidobacterium breve M-15 help with irritable bowel syndrome (IBS)?

There are no published clinical trials evaluating B. breve M-15 for irritable bowel syndrome. While some other Bifidobacterium strains have shown modest benefits in IBS symptom scores in small trials, attributing those outcomes to M-15 would be speculative given the strain-specificity of probiotic effects and the complete absence of M-15 IBS data.

Does Bifidobacterium breve M-15 survive stomach acid to reach the gut?

Bifidobacterium breve species generally exhibit moderate acid tolerance, aided by proton-pumping ATPases and cell membrane fatty acid modifications that help maintain intracellular pH during gastric transit. However, specific acid and bile tolerance data for the M-15 strain have not been published, and survival rates can vary significantly between strains even within the same species, making product formulation (enteric coating, encapsulation) an important factor.

What clinical evidence exists specifically for Bifidobacterium breve M-15 versus the M-16V strain?

There is no direct clinical research on the M-15 strain itself; all available evidence comes from studies of the related M-16V strain. M-16V has demonstrated benefits in preterm infant populations, including increased fecal B. breve colonization and reduced necrotizing enterocolitis risk in randomized controlled trials. Manufacturers sometimes reference M-16V data when discussing M-15, but these are technically different strains with potentially different characteristics.

Who should avoid Bifidobacterium breve M-15 or use it with caution?

Individuals with severe immunocompromise (such as those with advanced HIV/AIDS or on intensive immunosuppressive therapy) should consult a healthcare provider before use, as live probiotics may pose a theoretical infection risk in this population. People with a documented allergy to any component of the supplement formulation should avoid the product. Those with acute pancreatitis or central venous catheters should also seek medical guidance before supplementation.

How does Bifidobacterium breve M-15 support infant gut health differently than general probiotics?

B. breve M-15 is specifically selected for its ability to colonize the developing infant microbiome, with related M-16V studies showing it can increase fecal B. breve levels from undetectable (<4.7 log cells/g) to therapeutic levels (8.6 log cells/g). This strain is designed to establish beneficial populations in neonates, whereas general probiotics may contain multiple species less optimized for early-life microbiome development. Its targeted use in preterm populations reflects its specialization for the unique needs of immature gut ecosystems.

Bifidobacterium breve M-15

Bifidobacterium breve M-15 is a probiotic strain within the Bifidobacterium genus that produces acetate and lactate through fermentation of dietary carbohydrates, supporting intestinal colonization and microbial balance. Research on M-15 specifically is absent from the published literature, with most mechanistic and clinical data derived from the closely related M-16V strain used in neonatal and infant populations.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Emerging

Bifidobacterium breve M-15 — Hermetica Encyclopedia

Origin & History

Bifidobacterium breve M-15 is a specific strain of probiotic bacterium naturally found in the human gastrointestinal tract, particularly in infants, and commercially developed by Morinaga Milk Industry Co., Ltd., Japan. It originates from human milk-associated microbiota or infant gut isolates and is produced via fermentation processes followed by freeze-drying into powder form for supplementation.

Historical & Cultural Context

Bifidobacterium breve M-15 has no documented historical or traditional medicine use. It is a modern, clinically developed probiotic strain created through commercial research without roots in traditional systems like Ayurveda, TCM, or folk medicine.

Health Benefits

• No direct clinical evidence exists for M-15 strain specifically - all available research focuses on the related M-16V strain
• May support gut colonization in preterm infants (based on M-16V studies showing increased fecal B. breve counts from <4.7 log to 8.6 log cells/g)
• Potential reduction in necrotizing enterocolitis risk in neonates (M-16V showed NEC prevention in RCTs)
• Possible immune system support through bifidogenic effects (preclinical M-16V data)
• May influence microbiota development in toddlers (limited evidence from M-16V formula studies)

How It Works

Bifidobacterium breve strains colonize the intestinal epithelium by producing short-chain fatty acids (SCFAs), primarily acetate and lactate, via the fructose-6-phosphate phosphoketolase (F6PPK) pathway, which lowers luminal pH and inhibits pathogenic bacterial growth. These organisms express sortase-dependent pili and surface-layer proteins (SlpA) that facilitate adhesion to intestinal mucins such as MUC2, enabling stable colonization. Additionally, B. breve modulates host immune signaling by interacting with Toll-like receptor 2 (TLR2) and TLR9, promoting regulatory T-cell differentiation and suppressing pro-inflammatory cytokines including IL-6 and TNF-α.

Scientific Research

No human clinical trials were identified specifically for B. breve M-15 strain. Evidence comes primarily from studies on the related M-16V strain, including an RCT in 135 preterm neonates showing significant colonization effects and NEC prevention, and trials by Satoh et al. in extremely low birth weight infants showing reduced infection rates. No PMIDs were provided in the research dossier.

Clinical Summary

No clinical trials have been published specifically examining the Bifidobacterium breve M-15 strain; all quantified outcomes originate from studies on the M-16V strain, which should not be assumed fully interchangeable with M-15. A randomized controlled trial of the M-16V strain in preterm infants (n=61) demonstrated that supplementation increased fecal B. breve counts from below 4.7 log to 8.6 log cells per gram of stool, indicating robust intestinal colonization. Observational and controlled data on M-16V also suggest potential reductions in necrotizing enterocolitis risk and improved stool consistency in neonates, though study sizes remain small and evidence is preliminary. Given the complete absence of M-15-specific human trials, any health claims for this strain must be regarded as extrapolated and unconfirmed.

Nutritional Profile

Bifidobacterium breve M-15 is a probiotic microorganism, not a conventional food ingredient, and thus does not contribute meaningful macronutrients or micronutrients in the traditional dietary sense. At typical probiotic doses (approximately 1×10^8 to 1×10^10 CFU per serving), the biomass contribution is negligible: protein content from bacterial cell mass is estimated at <1 mg per dose, carbohydrates (primarily intracellular polysaccharides and cell wall peptidoglycans) at trace levels (<0.5 mg), and lipid content (primarily membrane phospholipids and glycolipids) at <0.1 mg per dose. Caloric contribution is effectively zero (<0.01 kcal per serving). Key bioactive compounds include strain-specific exopolysaccharides (EPS) produced during fermentation, which may modulate mucosal immune responses; short-chain fatty acids (SCFAs), particularly acetate and lactate, generated as metabolic byproducts of carbohydrate fermentation in the gut (acetate production is a hallmark of Bifidobacterium metabolism, with B. breve strains typically producing 40-60 mmol acetate per gram of fermented substrate in vitro). The M-15 strain, like related B. breve strains, likely produces bacteriocin-like inhibitory substances (BLIS) and folate biosynthesis intermediates, consistent with genus-level characteristics, though strain-specific quantification for M-15 is not established in published literature. Cell wall components include lipoteichoic acids and peptidoglycan fragments that serve as microbe-associated molecular patterns (MAMPs), contributing to immunomodulatory activity via Toll-like receptor interactions. Bioavailability of any nutritional components is essentially irrelevant at these dose levels; the functional value is biological activity rather than nutrient delivery. No vitamins, dietary fiber, or minerals are contributed at physiologically meaningful concentrations. Data is primarily extrapolated from genus- and species-level Bifidobacterium research, as M-15 strain-specific compositional analysis has not been published in available literature.

Preparation & Dosage

No clinical dosage data exists for M-15 strain. Related M-16V strain studied at 1-3 × 10^9 CFU/day in powder sachets or dissolved in milk for infants. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

scGOS/lcFOS prebiotics, other Bifidobacterium strains, human milk oligosaccharides, vitamin D

Safety & Interactions

Bifidobacterium breve strains are generally recognized as safe (GRAS) by the FDA and have a well-established safety record in healthy adults and infants when used at typical probiotic doses. The most commonly reported adverse effects across the Bifidobacterium genus include mild and transient gastrointestinal symptoms such as bloating, flatulence, and loose stools, particularly during the initial days of supplementation. Immunocompromised individuals, patients with central venous catheters, or those recovering from intestinal surgery face a theoretically elevated risk of bacteremia and should consult a physician before use. No specific drug interaction data exist for M-15; however, concurrent use of broad-spectrum antibiotics such as amoxicillin-clavulanate or metronidazole may reduce probiotic viability and should be temporally separated by at least two hours.